ArriVent Doses First Patient in Global Phase 3 ALPACCA Study for Firmonertinib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy ARVN?
ArriVent BioPharma announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cancer, NSCLC. "Initiation of our pivotal Phase 3 ALPACCA trial marks an important milestone in our strategy to expand the global reach of firmonertinib," said Bing Yao, Ph.D., Chairman and Chief Executive Officer of ArriVent. "Patients with EGFR PACC mutant NSCLC currently have limited treatment options and represent a clear unmet medical need. With a well-characterized safety profile and broad clinical systemic and central nervous system activity in patients, we believe firmonertinib is strongly positioned to bring meaningful innovation to NSCLC patients with PACC mutations and the potential to become a cornerstone therapy across the EGFR mutant spectrum."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARVN
Wall Street analysts forecast ARVN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.380
Low
15.00
Averages
16.00
High
18.00
Current: 13.380
Low
15.00
Averages
16.00
High
18.00
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arvinas, Inc. Q4 2025 Earnings Call Insights
- New Drug Application Milestone: Arvinas is submitting its first new drug application, potentially leading to the first-ever FDA approval of a PROTAC degrader, marking the company’s entry into a period with multiple value-driving milestones that could boost stock prices and enhance market confidence.
- Clinical Trial Progress: The company is focusing resources on four Phase I clinical programs, including ARV-102 and ARV-806, with plans to share new clinical data in 2026, indicating strong anticipation for future data readouts that may bolster investor confidence in long-term growth.
- Strong Financial Position: As of the fourth quarter, Arvinas reported over $685 million in cash and cash equivalents, although down from over $1 billion at the end of 2024, it maintains guidance for cash runway into the second half of 2028, ensuring continued investment capability.
- Effective Cost Control: General and administrative expenses for the fourth quarter were $23 million, significantly down from $34.1 million in the prior year, reflecting effective cost control measures in personnel and infrastructure, further enhancing financial flexibility.
See More
Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline
- Earnings Miss: Arvinas reported a Q4 GAAP EPS of -$1.10, missing expectations by $0.62, indicating significant challenges in profitability for the company.
- Revenue Decline: The company generated $9.5 million in revenue, an 84% year-over-year decrease, falling short of the expected $27.76 million, reflecting weak market demand and insufficient sales strategies.
- Cash Flow Outlook: Arvinas believes that its cash, cash equivalents, and marketable securities as of December 31, 2025, will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2028, indicating a degree of financial stability.
- Leadership Transition: The appointment of a new president and CEO has been announced, and this leadership change may impact the company's strategic direction and future development.
See More
Arvinas Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Schedule: Arvinas is set to release its Q4 earnings on February 24 before market open, with a consensus EPS estimate of -$0.57, reflecting a 9.5% year-over-year decline, indicating challenges in profitability.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $37.26 million, representing a 37.1% year-over-year decrease, which highlights pressures on the company from market competition and product sales, potentially impacting investor confidence.
- Earnings Estimate Adjustments: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, suggesting a weakening analyst confidence in the company's future performance, which may lead to stock price volatility.
- Leadership Transition: Arvinas has announced the appointment of a new president and CEO, and this leadership change could influence the company's strategic direction and market performance, prompting investors to monitor the new leadership's policies and execution capabilities.
See More
Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop
- CEO Appointment Context: Arvinas appointed Randy Teel as CEO after a comprehensive search, succeeding John Houston, which led to an 11% drop in stock price on Thursday, indicating market concerns over the leadership change.
- Leadership Experience: Teel, previously the Chief Business Officer, played a crucial role in the company's 2018 IPO, bringing extensive industry experience that is expected to positively impact the company's clinical-stage biotechnology development.
- Strategic Direction Shift: Teel stated that the company will focus on earlier-stage clinical programs, aiming to leverage the PROTAC degrader platform to transform treatment paradigms for serious diseases, a strategic shift that could influence future R&D directions and market positioning.
- Market Reaction: Despite the stock drop, sentiment on Stocktwits for ARVN shifted from 'neutral' to 'bullish', with some users viewing the decline as an overreaction, reflecting confidence in the new CEO's capabilities.
See More
Arvinas Appoints New CEO and Board Chair
- Executive Changes: Arvinas has appointed Randy Teel as the new CEO and president, effective immediately, with Teel previously serving as the chief business officer, where he played a crucial role in driving corporate growth and industry partnerships, indicating a strategic focus on continued development.
- Board Restructuring: Teel will also serve as a board member, succeeding the retiring John Houston, who will remain on the board and provide consulting services, ensuring stability and continuity during this transition period for the company.
- New Board Chair: Briggs Morrison has been elected as the new chair of the board, effective immediately, with this leadership change aimed at strengthening corporate governance and enhancing decision-making efficiency to address industry challenges.
- Market Reaction: Although Arvinas' assets are viewed as mediocre, the market shows cautious optimism regarding the new executive appointments, which may influence the company's future stock performance.
See More
Analysis of Rapid Growth in the PROTAC Market
- Market Size Forecast: The PROTAC market is expected to experience significant growth by 2034 in leading markets, driven by an increase in clinical trial drugs targeting various cancers such as HR+/HER2− breast cancer, indicating accelerated investment and R&D activities in this field.
- Patient Population Analysis: The report highlights that approximately 85% of patients diagnosed with metastatic breast cancer had an early-stage diagnosis, emphasizing the treatment needs for early-stage patients and further driving the development and market potential of PROTAC drugs.
- Drug Development Dynamics: Leading companies like Arvinas, Pfizer, and Novartis are developing multiple PROTAC drugs, including Vepdegestrant and Luxdegalutamide, with clinical trial results directly impacting market competition and future treatment standards.
- Collaboration and Investment Opportunities: Novartis's upfront payment of $150 million for Arvinas's ARV-766 demonstrates large pharmaceutical companies' recognition and investment willingness in PROTAC technology, providing strong support for future clinical collaborations and market promotion.
See More
Arvinas, Inc. Q4 2025 Earnings Call Insights
- New Drug Application Milestone: Arvinas is submitting its first new drug application, potentially leading to the first-ever FDA approval of a PROTAC degrader, marking the company’s entry into a period with multiple value-driving milestones that could boost stock prices and enhance market confidence.
- Clinical Trial Progress: The company is focusing resources on four Phase I clinical programs, including ARV-102 and ARV-806, with plans to share new clinical data in 2026, indicating strong anticipation for future data readouts that may bolster investor confidence in long-term growth.
- Strong Financial Position: As of the fourth quarter, Arvinas reported over $685 million in cash and cash equivalents, although down from over $1 billion at the end of 2024, it maintains guidance for cash runway into the second half of 2028, ensuring continued investment capability.
- Effective Cost Control: General and administrative expenses for the fourth quarter were $23 million, significantly down from $34.1 million in the prior year, reflecting effective cost control measures in personnel and infrastructure, further enhancing financial flexibility.
See More
Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline
- Earnings Miss: Arvinas reported a Q4 GAAP EPS of -$1.10, missing expectations by $0.62, indicating significant challenges in profitability for the company.
- Revenue Decline: The company generated $9.5 million in revenue, an 84% year-over-year decrease, falling short of the expected $27.76 million, reflecting weak market demand and insufficient sales strategies.
- Cash Flow Outlook: Arvinas believes that its cash, cash equivalents, and marketable securities as of December 31, 2025, will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2028, indicating a degree of financial stability.
- Leadership Transition: The appointment of a new president and CEO has been announced, and this leadership change may impact the company's strategic direction and future development.
See More
Arvinas Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Schedule: Arvinas is set to release its Q4 earnings on February 24 before market open, with a consensus EPS estimate of -$0.57, reflecting a 9.5% year-over-year decline, indicating challenges in profitability.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $37.26 million, representing a 37.1% year-over-year decrease, which highlights pressures on the company from market competition and product sales, potentially impacting investor confidence.
- Earnings Estimate Adjustments: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, suggesting a weakening analyst confidence in the company's future performance, which may lead to stock price volatility.
- Leadership Transition: Arvinas has announced the appointment of a new president and CEO, and this leadership change could influence the company's strategic direction and market performance, prompting investors to monitor the new leadership's policies and execution capabilities.
See More
Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop
- CEO Appointment Context: Arvinas appointed Randy Teel as CEO after a comprehensive search, succeeding John Houston, which led to an 11% drop in stock price on Thursday, indicating market concerns over the leadership change.
- Leadership Experience: Teel, previously the Chief Business Officer, played a crucial role in the company's 2018 IPO, bringing extensive industry experience that is expected to positively impact the company's clinical-stage biotechnology development.
- Strategic Direction Shift: Teel stated that the company will focus on earlier-stage clinical programs, aiming to leverage the PROTAC degrader platform to transform treatment paradigms for serious diseases, a strategic shift that could influence future R&D directions and market positioning.
- Market Reaction: Despite the stock drop, sentiment on Stocktwits for ARVN shifted from 'neutral' to 'bullish', with some users viewing the decline as an overreaction, reflecting confidence in the new CEO's capabilities.
See More
Arvinas Appoints New CEO and Board Chair
- Executive Changes: Arvinas has appointed Randy Teel as the new CEO and president, effective immediately, with Teel previously serving as the chief business officer, where he played a crucial role in driving corporate growth and industry partnerships, indicating a strategic focus on continued development.
- Board Restructuring: Teel will also serve as a board member, succeeding the retiring John Houston, who will remain on the board and provide consulting services, ensuring stability and continuity during this transition period for the company.
- New Board Chair: Briggs Morrison has been elected as the new chair of the board, effective immediately, with this leadership change aimed at strengthening corporate governance and enhancing decision-making efficiency to address industry challenges.
- Market Reaction: Although Arvinas' assets are viewed as mediocre, the market shows cautious optimism regarding the new executive appointments, which may influence the company's future stock performance.
See More
Analysis of Rapid Growth in the PROTAC Market
- Market Size Forecast: The PROTAC market is expected to experience significant growth by 2034 in leading markets, driven by an increase in clinical trial drugs targeting various cancers such as HR+/HER2− breast cancer, indicating accelerated investment and R&D activities in this field.
- Patient Population Analysis: The report highlights that approximately 85% of patients diagnosed with metastatic breast cancer had an early-stage diagnosis, emphasizing the treatment needs for early-stage patients and further driving the development and market potential of PROTAC drugs.
- Drug Development Dynamics: Leading companies like Arvinas, Pfizer, and Novartis are developing multiple PROTAC drugs, including Vepdegestrant and Luxdegalutamide, with clinical trial results directly impacting market competition and future treatment standards.
- Collaboration and Investment Opportunities: Novartis's upfront payment of $150 million for Arvinas's ARV-766 demonstrates large pharmaceutical companies' recognition and investment willingness in PROTAC technology, providing strong support for future clinical collaborations and market promotion.
See More
